التفاصيل البيبلوغرافية
| العنوان: |
Evaluation of the implementation of a novel pharmacogenetics panel test in the Helsinki and Uusimaa Hospital District (HUS) |
| المؤلفون: |
Sjöblom, Ann-Sophie |
| المساهمون: |
Åbo Akademi, Fakulteten för naturvetenskaper och teknik, Farmaci |
| سنة النشر: |
2023 |
| المجموعة: |
Doria (National Library of Finland / |
| مصطلحات موضوعية: |
pharmacogenetics panel test, genotyping, genotype frequency, genotype-predicted phenotype, pharmacogenetics, tests, introduction (implementation), evaluation, genotype, phenotype, data, farmakogenetik, test, ibruktagande, utvärdering, genotyp, fenotyp, farmakogenetiikka, testit, käyttöönotto, arviointi, genotyyppi, fenotyyppi, 317 Farmaci |
| الوصف: |
Interindividual differences in how we respond to drugs can make it difficult to fully achieve rational pharmacotherapy. Genetic variation, together with other factors, dictates the dose response and the profile of adverse drug reactions of a drug in a patient. It is possible to genotype patients in order to draw conclusions about their genetics and thereby adjust their medication accordingly. HUSLAB introduced a pharmacogenetics panel test at the beginning of 2022. The panel test includes 12 of the most common pharmacogenes with clinical impact, and their genetic variants. The aim of this Master’s Thesis was to evaluate the implementation of the new pharmacogenetics panel test at the Hospital District of Helsinki and Uusimaa (HUS). I looked at a sample of tests performed at HUSLAB during a six-month period in 2022 and compared it to the corresponding six-month period of the previous year. The study compared the frequencies of clinically actionable genotypes and phenotypes by assessing the gene variants and alleles, genotypes, and genotype-predicted phenotypes. Additionally, the number of performed tests and the sending units were compared. The study was conducted as a descriptive retrospective registry study. The pharmacogenetics panel test results from 1st of February 2022 to 31st of July 2022 and the single-gene test results from 1st of February 2021 to 31st of July 2021 served as research material. The phenotype frequencies were compared between the two study periods and are presented with 95% confidence intervals. The genotype-predicted phenotype was refined for five of the tested genes by the implementation of the panel test due to more gene variants being analyzed in the panel test. The impact of the refined phenotype is better quality data for clinical decision making based on the pharmacogenetic test results. The total quantity of tests performed during the two review periods showed that the pharmacogenetic testing coverage has increased significantly since the implementation of the panel test. Oncology ... |
| نوع الوثيقة: |
thesis |
| وصف الملف: |
true |
| اللغة: |
English |
| العلاقة: |
https://www.doria.fi/handle/10024/187267Test; URN:NBN:fi-fe2023051544540 |
| الإتاحة: |
https://www.doria.fi/handle/10024/187267Test |
| حقوق: |
This publication is copyrighted. You may download, display and print it for Your own personal use. Commercial use is prohibited. ; Publikationen är skyddad av upphovsrätten. Den får läsas och skrivas ut för personligt bruk. Användning i kommersiellt syfte är förbjuden. ; Julkaisu on tekijänoikeussäännösten alainen. Teosta voi lukea ja tulostaa henkilökohtaista käyttöä varten. Käyttö kaupallisiin tarkoituksiin on kielletty. ; sv=Avhandlingen kan enbart läsas vid Boktornet och Academillbiblioteket.|fi=Kokoteksti on luettavissa vain Kirjatornissa ja Academill-kirjastossa.|en=Full-text can be read only at the Book Tower and Academill Library.| |
| رقم الانضمام: |
edsbas.4B6F96E6 |
| قاعدة البيانات: |
BASE |
